← Leaderboards
James L Mohler
University Of North Carolina Chapel Hill
$8,721,215
Attributed
$8,721,215
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.3M · FY2005–21$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$19,041,071 · 10
By mechanism
P01$17,501,715 · 7
M01$676,049 · 1
P30$441,498 · 1
R21$421,809 · 1
Top collaborators
- Frank S French5 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Fulton T Crews$34,208,071
- Bahjat F Qaqish$2,033,075
- Edward L Lecluyse$571,033
Others in their field
Top investigators on “Androgen Receptor”
- Susan E. Hankinson · University Of Massachusetts Amherst$24,278,267
- Diane E Merry · Thomas Jefferson University$17,810,180
- Charles L Sawyers · Sloan-Kettering Inst Can Research$17,232,913
- Richard D Schulick · Johns Hopkins University$17,086,121
- Shalendar Bhasin · La Biomed Res Inst/ Harbor Ucla Med Ctr$16,194,198
- Xiaoqi Liu · Harvard University$15,300,481
Research focus
Androgen ReceptorAndrogensTissuesAndrogen MetabolismRecurrenceMalignant Neoplasm Of ProstateProstate NeoplasmsXenograft ProcedureProstateCastrationEnzymesResearch PersonnelGrowthDeprivationXenograft ModelSpecimenProgramsImmunohistochemistryProteinsClinical TrialsPathway InteractionsInterestGrowth FactorClinical Research
Grant awards (47)
Bioanalytics, Metabolomics and Pharmacokinetics Shared Resource$147,166
P30 · FY2021 · CA · contact PI
Bioanalytics, Metabolomics and Pharmacokinetics Shared Resource$147,166
P30 · FY2020 · CA · contact PI
Bioanalytics, Metabolomics and Pharmacokinetics Shared Resource$147,166
P30 · FY2019 · CA · contact PI
A Small-Molecule Inhibitor of the Terminal Steps for Intracrine Androgen Synthesis in Advanced Prostate Cancer$259,734
R21 · FY2017 · CA · contact PI
A Small-Molecule Inhibitor of the Terminal Steps for Intracrine Androgen Synthesis in Advanced Prostate Cancer$162,075
R21 · FY2016 · CA · contact PI
Prostate Cancer: Transition to Androgen - Independence (CA77739)$1,433,904
P01 · FY2014 · CA
Interference with Androgen Receptor and Its Ligands$482,310
P01 · FY2014 · CA · contact PI
ImmunoAnalysis and Research Specimen Management$191,951
P01 · FY2014 · CA · contact PI
Prostate Cancer: Transition to Androgen - Independence (CA77739)$590,689
P01 · FY2013 · CA
Interference with Androgen Receptor and Its Ligands$196,510
P01 · FY2013 · CA · contact PI
ImmunoAnalysis and Research Specimen Management$80,302
P01 · FY2013 · CA · contact PI
Prostate Cancer: Transition to Androgen - Independence (CA77739)$1,485,030
P01 · FY2012 · CA
Interference with Androgen Receptor and Its Ligands$494,453
P01 · FY2012 · CA · contact PI
ImmunoAnalysis and Research Specimen Management$202,115
P01 · FY2012 · CA · contact PI
Prostate Cancer: Transition to Androgen - Independence (CA77739)$1,488,639
P01 · FY2011 · CA
Interference with Androgen Receptor and Its Ligands$347,662
P01 · FY2011 · CA · contact PI
ImmunoAnalysis and Research Specimen Management$229,785
P01 · FY2011 · CA · contact PI
Prostate Cancer: Transition to Androgen - Independence (CA77739)$1,514,460
P01 · FY2010 · CA
Interference with Androgen Receptor and Its Ligands$633,005
P01 · FY2010 · CA · contact PI
ImmunoAnalysis and Research Specimen Management$173,902
P01 · FY2010 · CA · contact PI
Project 1$450,019
P01 · FY2009 · CA · contact PI
CORE B$175,033
P01 · FY2009 · CA · contact PI
Project 1$439,152
P01 · FY2008 · CA · contact PI
CORE B$171,346
P01 · FY2008 · CA · contact PI
Project 1$441,701
P01 · FY2007 · CA · contact PI
CORE B$170,551
P01 · FY2007 · CA · contact PI
Project 1$339,042
P01 · FY2006 · CA · contact PI
CORE B$127,070
P01 · FY2006 · CA · contact PI
Project 1$346,087
P01 · FY2005 · CA
CORE B$97,497
P01 · FY2005 · CA
PROSTATE CANCER: TRANSITION TO ANDROGEN-INDEPENDENCE$333,487
P01 · FY2003 · CA
PROSTATE CANCER: TRANSITION TO ANDROGEN-INDEPENDENCE$1,182,577
P01 · FY2002 · CA
CORE--IMMUNOANALYSIS$208,271
P01 · FY2002 · CA
ANDROGEN RECEPTOR EXPRESSION AND FUNCTION IN PROSTATE CANCER$208,271
P01 · FY2002 · CA
BISPECIFIC ANTIBODY MDX H210 COMBINED W/ GM CSF IN PROSTATE CANCER$190,747
M01 · FY2002 · RR
PROSTATE CANCER: TRANSITION TO ANDROGEN-INDEPENDENCE$1,164,524
P01 · FY2001 · CA
BISPECIFIC ANTIBODY MDX H210 COMBINED W/ GM CSF IN PROSTATE CANCER$294,555
M01 · FY2001 · RR
ANDROGEN RECEPTOR EXPRESSION AND FUNCTION IN PROSTATE CANCER$208,271
P01 · FY2001 · CA
CORE--IMMUNOANALYSIS$208,271
P01 · FY2001 · CA
BISPECIFIC ANTIBODY MDX H210 COMBINED W/ GM CSF IN PROSTATE CANCER$190,747
M01 · FY2001 · RR
PROSTATE CANCER: TRANSITION TO ANDROGEN-INDEPENDENCE$1,126,546
P01 · FY2000 · CA
CORE--IMMUNOANALYSIS$279,641
P01 · FY2000 · CA
ANDROGEN RECEPTOR EXPRESSION AND FUNCTION IN PROSTATE CANCER$279,641
P01 · FY2000 · CA
ANTIBODY MDX H210 COMBINED W/ GM CSF IN PROSTATE CANCER$0
M01 · FY2000 · RR
ANTIBODY MDX H210 COMBINED W/ GM CSF IN PROSTATE CANCER$0
M01 · FY2000 · RR
ANTIBODY MDX H210 COMBINED W/ GM CSF IN PROSTATE CANCER$0
M01 · FY2000 · RR
ANTIBODY MDX H210 COMBINED W/ GM CSF IN PROSTATE CANCER$0
M01 · FY2000 · RR